A new report published in The Lancet Diabetes & Endocrinology challenges the conventional definition of obesity, and urges a shift from the reliance on Body Mass Index (BMI) to a more nuanced approach. This is supported by over 50 global medical experts. The report also recommends splitting the term "obesity" into two categories: "Clinical obesity" and "Pre-clinical obesity". This aims to improve diagnosis and treatment for over a billion people worldwide living with obesity.

Clinically Obese

This applies to individuals whose obesity has progressed to a disease state, manifesting in organ damage, heart disease, type 2 diabetes, or other health complications. These individuals could also experience symptoms like breathlessness, joint pain, or impaired daily functioning. Treatment also involves medical interventions, including weight-loss medications or surgery.

Pre-Clinic Obese

Whereas the term "pre-clinic obese" refers to those who are overweight but not yet exhibiting health issues. While they may be at risk of developing obesity-related conditions, their organ function and overall health remain intact. What they need is preventive care, which includes dietary guidance, counselling, and regular monitoring to avoid and reduce future health risks.

What does the study say?

The study, led by Professor Francesco Rubino from King's College London emphasizes that obesity is not one-size-fits-all condition. This means it should rather be treated as a spectrum as some individuals maintain normal organ function despite being classified as obese. There are others who may face severe health complications too. However, the current method of calculating obesity based on BMI often leads to misdiagnosis or inadequate care.

The report also states that BMI, while is useful for analyzing population trends, is a flawed unit of measuring individual health. Therefore, there is a need to redefine obesity, and healthcare professionals can provide more precise care by distinguishing those who need immediate medical intervention and those who require preventive strategies.

Limitations of BMI, Why It Falls Short?

BMI is used to classify individuals as underweight, healthy weight, overweight, or obese based on their height and weight. It is calculated by dividing weight in kilograms by health in meters squared. However, there are reasons while it falls short.

•Muscle vs Fat: Athletes or muscular individuals often have high BMIs despite the low body fat

•Fat Distribution: BMI does not measure fat around the waist or organs, which could be more dangerous to one's health.

•Individual Health Variation: It also overlooks the specific health conditions such as heart diseases or diabetes, or any other, while evaluating a person's category in terms of weight.

ALSO READ: Is It Time To Say Goodbye To BMI?

Scope Of Study

By redefining obesity, the study could transform the approach to diagnosis and treatment. It can focus on individual health risks rather than BMI alone. Healthcare providers can also offer tailored care. This also will ensure hat weight-loss medications like Wegovy or Mounjaro are prescribed only to those who genuinely require it.

As per Professor Louise Baur from the University of Sydney, a Children's obesity expert said that this redefinition allows both adults and children to receive more appropriate care while reducing over-diagnosis and unnecessary treatments.

The United States has signed 24 bilateral health Memoranda of Understanding or MoUs with Latin America and African countries under the Trump administration's America First Global Health Strategy.

The first agreement with Panama is described as “strengthening Western hemisphere health security”, which it added is “a priority”. Thereafter, four Latin American agreements too involve smaller grants and focus on disease surveillance. Other 20 agreements all with African countries who have been previous recipients of health grants via the now disbanded US agency for International Development or USAID and decimated US President's Emergency Funds for AIDS Relief (PEPFAR).

The five-year MoUs aim to quickly shift financial responsibility for key health services to national governments. In several countries, including Kenya, Uganda and the Democratic Republic of Congo (DRC), more than half of HIV programme funding has traditionally come from donors, particularly the United States. In the DRC, for instance, at least half of the antiretroviral medicines used have been financed by the US.

What Do These MoUs Comprise?

The transitional Memorandums of Understanding (MoUs) signed between the United States and several countries come with a major condition. They require strong investment in infectious disease surveillance systems.

The goal is to ensure that pathogen information from outbreaks is shared with the US within a week. Officials say this helps detect global threats early and protect public health.

At the same time, it gives US pharmaceutical companies early access to pathogen data, allowing them to develop vaccines, medicines and diagnostics more quickly.

The US–DRC Health Agreement

The United States and the Democratic Republic of Congo (DRC) signed their health MoU on 26 February. According to the US State Department, the agreement focuses on strengthening the country’s ability to detect and contain infectious disease outbreaks before they spread internationally.

• The focus reflects the country’s recent health challenges.
• The DRC has experienced several Ebola outbreaks in recent years.
• It is also dealing with the world’s largest mpox outbreak.

Funding Commitments

Under the agreement:

• The US will invest up to $900 million over five years
• The DRC will increase its health spending by $300 million

Most of the funding will support a national integrated surveillance and outbreak response system.

This includes:

• A laboratory network capable of detecting outbreaks within seven days
• Faster outbreak investigations and response systems
• Coordination between the US and other global health partners

The MoU also aims to modernize health data systems through electronic medical records, interoperable platforms, better trained community health workers and expanded services for HIV, tuberculosis, malaria, polio and maternal and child health.

Minerals Before Health

In several cases, health agreements were preceded by deals related to natural resources.

The United States and the DRC first signed a strategic partnership on critical minerals. The deal aims to secure supplies of minerals needed for commercial and defense industries.

The DRC is one of the world’s largest sources of rare earth minerals, including cobalt and copper. China has historically dominated the purchasing and processing of these resources.

Recently, the DRC has begun opening its mineral sector to US investors. According to Reuters, the government sent Washington a shortlist of state owned assets involving:

• manganese
• copper
• cobalt
• gold
• lithium

Guinea followed a similar path. It signed a minerals MoU with the US on 5 February, followed by a health MoU on 27 February. The health agreement prioritizes strengthening laboratory networks and improving biosafety standards by 2027.

Legal Pushback and Rejected Deals

Not all countries are comfortable linking health support to access to resources or data.

In the DRC, a group of lawyers has challenged the minerals agreement in the Constitutional Court. They argue that the deal violates the constitution and undermines national sovereignty over natural resources.

Zimbabwe also withdrew from negotiations with the US over a similar agreement.

Officials said the country was asked to share biological resources and outbreak data for years without any guarantee that vaccines, treatments or diagnostics developed from that data would be available to Zimbabwe if a future crisis occurred. They also said the US did not offer reciprocal sharing of its own epidemiological data.

Concerns in Kenya and Zambia

Kenya’s agreement with the United States has also faced legal hurdles. The country’s High Court halted the MoU after two court challenges questioned provisions that could allow the US access to patient data and pathogen information.

Zambia has also expressed reservations about its proposed health deal with Washington. The agreement stalled after the US linked the billion dollar package to cooperation in the country’s mining sector, particularly copper and cobalt.

Zambia has since asked for revisions, saying parts of the deal do not align with its national interests.

Critics Call the Policy “Extractive”

Some experts argue that these agreements reflect a broader shift in US global health policy.

Sophie Harman, professor of international politics at Queen Mary University of London, wrote in the BMJ that extraction appears to be central to the approach.

According to her analysis, the policy focuses less on improving global health outcomes and more on strengthening US economic and geopolitical interests, including competition with China.

She warns that countries entering such agreements could risk giving up resources or scientific data while gaining relatively limited health benefits.

Rare diseases may be individually uncommon, but together they represent a large and persistent care gap. More than 300 million people globally live with a rare condition, and when families and caregivers are counted, the impact touches over one billion lives. The economic burden is estimated to exceed $7 trillion each year.

In India, the challenge is compounded by geography, uneven specialist availability and the lifelong nature of many rare conditions. The question is no longer whether the system recognises the need, but whether it can deliver continuous care at scale.

Why Patients Still Struggle To Reach Care

For most rare disease patients, the hardest part is not always the science but the pathway to care. Diagnosis is often delayed, sometimes by years. Patients move between providers carrying incomplete records. Specialist centres are concentrated in a few large cities, forcing families to travel repeatedly for consultations that may last only minutes. This is both financially draining and clinically inefficient.

Telemedicine is beginning to ease some of this pressure. Virtual consultations allow specialists to extend their reach beyond metropolitan clusters. For families in tier two and tier three locations, this can mean earlier clinical input and fewer avoidable journeys.

Remote monitoring tools are also shifting care from episodic hospital visits to continuous oversight, which is particularly valuable for conditions that require close tracking over time.

Why Data Matters More Than Ever

If access is the visible challenge, data fragmentation is the structural one. Rare disease information remains scattered across hospitals, laboratories and individual case files. This weak visibility affects everything from prevalence estimates to therapy development. Policymakers struggle to size the problem accurately. Clinicians miss longitudinal patterns. Industry investment becomes harder to justify.

Digital health systems can address this by creating longitudinal patient records that follow individuals across providers. Even relatively modest steps such as strengthening diagnostic reporting or building disease registries can significantly improve coordination. For rare diseases, where patient numbers are small and widely dispersed, structured data is not a luxury. It is the backbone of effective care.

India’s Digital Opportunity

India has begun building the rails needed for this transition. The Ayushman Bharat Digital Mission is creating a national health data architecture anchored in unique health IDs and interoperable records. If applied rigorously to rare diseases, this infrastructure can support lifelong patient tracking, improve referral accuracy and give policymakers clearer visibility into disease burden.

Interoperability will determine how far this effort goes. The growing adoption of FHIR standards and API led systems is slowly allowing previously disconnected hospital platforms to exchange clinical information. For rare disease patients, whose care often spans multiple providers and years of follow up, this continuity is not technical detail. It is essential to safe treatment.

AI Moves From Promise To Practice

Artificial intelligence is also starting to show practical value. Globally, AI based clinical decision support tools are being used to flag potential rare disease cases hidden within routine health records. This matters because many rare conditions present with non specific symptoms and are frequently missed in early stages.

Collaborations between technology firms and pharmaceutical companies are demonstrating how electronic health record analysis, suspect patient lists and longitudinal data can help clinicians triage cases earlier for confirmatory testing. As these tools mature and integrate into routine workflows, they could significantly shorten the diagnostic odyssey that rare disease families currently endure.

Engaging Patients Beyond The Clinic

At the patient level, the shift is becoming more practical and visible. Tools that let people log symptoms, get medication reminders and share updates in real time are helping them stay more consistent with treatment, while giving clinicians better insight between visits. For lifelong conditions, this kind of day to day support brings care into the flow of everyday life, where most disease management actually happens.

Federated data models add an important layer of trust. By enabling analysis across multiple small patient populations without moving sensitive personal data, they address both privacy concerns and the sample size limitations that have historically slowed rare disease research.

From Pilots to Systems

Progress is visible across both public and private sectors. Regulated digital health platforms are already supporting rare disease programmes in several countries. Industry collaborations are using AI to detect conditions that often go undiagnosed for years. Public genomic databases are generating new diagnoses by enabling experts to build on shared evidence.

India’s immediate task is to move beyond isolated pilots. Telemedicine networks must be tied to referral protocols and reimbursement pathways. Digital registries must be built with strong governance and patient trust. AI tools need to be embedded into everyday clinical workflows rather than remaining demonstration projects.

Why Investment Makes Fiscal Sense

Poorly managed rare diseases create avoidable hospitalisations, lost productivity and long term care costs. Evidence increasingly shows that targeted investments in data systems, screening and coordinated care can reduce downstream expenditure. For low- and middle-income countries working within tight health budgets, these are not marginal gains.

India already has many of the building blocks needed to improve rare disease care, from expanding digital health infrastructure to growing AI capabilities and increasing policy focus. The real test now is disciplined execution.

Telemedicine networks must deepen their reach, patient registries need to become reliable and usable, data must move securely across systems, and clinicians should have decision support tools that fit into everyday practice. Taken together, these steps can meaningfully narrow today’s access gaps.

Digital health will not make rare diseases any less complex. But if implemented thoughtfully, it can reduce distance, shorten delays and bring much needed continuity to care journeys that are currently fragmented. For families managing lifelong conditions, that would be a tangible and much overdue shift.

In India, it is not uncommon for families to travel across cities, sometimes across states, seeking answers for symptoms that simply don’t make sense. A child who is not meeting developmental milestones. A young adult with unexplained muscle weakness. Recurrent hospital visits with no clear diagnosis.

For many, this long and frustrating search for clarity is what medicine calls the diagnostic odyssey.

Rare diseases are individually uncommon, but collectively they affect millions of people worldwide. Rare diseases affect an estimated 263–446 million people worldwide, spanning every geography, healthcare system, and socioeconomic context. India alone is estimated to have 70 million people living with rare diseases.

Importantly, although 70%–80% of rare diseases are genetic in origin, routine medical practices often consider genetic testing only after years of inconclusive evaluations.

In India, this challenge is amplified by several factors, including limited awareness of rare conditions, uneven access to specialized testing across regions, and a tendency to treat symptoms individually rather than look for a unifying cause.

A child may see a neurologist for seizures, a gastroenterologist for feeding issues, and a developmental pediatrician for delays, without anyone connecting the dots.

Studies have shown that patients and their families frequently wait years before receiving a confirmed diagnosis. Globally, rare disease diagnosis can take anywhere between 5–30 years.

In a country like India, where healthcare expenses are often paid out-of-pocket, this prolonged uncertainty can be devastating. Beyond cost, there is the psychological toll; parents wondering if they missed something and adult patients often questioning whether their symptoms are “all in their head”. During this period, families undergo repeated tests, face conflicting opinions, and bear significant emotional and financial strains.

Research shows that families experience profound emotional burden during the diagnostic odyssey, including stress, anxiety, and feelings of isolation.

Why Do These Conditions Stay Undetected For Years?

In many cases, the explanation is written into a person’s DNA. Genetic disorders rarely announce themselves clearly; instead, they often mimic common illnesses. Fatigue may look like anemia, developmental delay may resemble a learning difficulty, and repeated infections might be treated as isolated events rather than part of a larger pattern. Because the symptoms overlap with more familiar conditions, doctors naturally begin by treating what appears most likely.

Most healthcare systems also follow a step-by-step diagnostic approach; rule out the common causes first, then move to less common ones if symptoms persist. While this method works well for typical illnesses, it can significantly delay answers for rare genetic conditions. Without looking directly at the genetic blueprint, the underlying cause may remain hidden, even as the visible symptoms are managed one at a time.

Today, advances in genomic technologies such as whole-exome sequencing (WES) and whole-genome sequencing (WGS) allow us to examine thousands of genes simultaneously. Rather than guessing which gene might be responsible, we can comprehensively analyze a patient’s DNA to search for answers.

Evidence increasingly supports the use of genomic sequencing earlier in the diagnosis and care of rare diseases. Similarly, studies highlight how genomic testing not only provides diagnoses but also directly influences treatment decisions and long-term care planning.

In the Indian context, integrating genetic testing earlier could transform care. Instead of years of fragmented consultations, patients could receive a precise diagnosis sooner. This clarity can:

• Prevent unnecessary or repeated investigations
• Guide appropriate treatment strategies
• Inform family members about potential risks
• Enable informed decisions about future pregnancies
• Equally important, it replaces uncertainty with understanding.

Encouragingly, awareness around rare diseases is growing in India, and conversations around early genomic testing are becoming more mainstream. As technology becomes more affordable and accessible, we have an opportunity to fundamentally change the patient journey.

No family should spend years searching for answers when science has the tools to help. By embracing genomic medicine earlier in the diagnostic pathway, we can shorten the odyssey, reduce suffering, and empower families with clarity.

Because when symptoms don’t add up, sometimes the answer lies written in our genes.